COMPANY RESEARCHJiangsu Yahong Meditech Co., Ltd.
Jiangsu Yahong Meditech, also known as Asieris Pharmaceuticals, is a Chinese biotechnology company developing therapeutics for oncology and related urologic conditions. Its work includes discovery, clinical development and commercialization-oriented research for serious diseases, with particular experience in drug candidates designed for specialized patient populations. The company is listed on the Shanghai Stock Exchange STAR Market under code 688176 and maintains corporate operations in China. This directory treats it as an innovative drug developer rather than a contract-service provider, while keeping its changing individual development programs outside the permanent profile.
Company at a glance
Corporate information
- Company entity
- Jiangsu Yahong Meditech Co., Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.asieris.cn/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE STAR: 688176
small molecules · oncology drug development
oncology · urologic diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Jiangsu Yahong Meditech, also known as Asieris Pharmaceuticals, is a Chinese biotechnology company developing therapeutics for oncology and related urologic conditions. Its work includes discovery, clinical development and commercialization-oriented research for serious diseases, with particular experience in drug candidates designed for specialized patient populations. The company is listed on the Shanghai Stock Exchange STAR Market under code 688176 and maintains corporate operations in China. This directory treats it as an innovative drug developer rather than a contract-service provider, while keeping its changing individual development programs outside the permanent profile.
Business, technology & evidence
- SecuritiesSSE STAR: 688176
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Jiangsu Yahong Meditech Co., Ltd. ↗Jiangsu Yahong Meditech Co., Ltd. ·
- Official issuer and R&D disclosure · Jiangsu Yahong Meditech Co., Ltd. ↗Jiangsu Yahong Meditech Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.